A protective antibody was produced in 7 days.

Qingdao Daily/Guanhai News July 27th. Qingdao Haihua Biological Group Co., Ltd. (hereinafter referred to as "Haihua Biological") developed a new type of coronary virus pneumonia, a pair of virus vaccine plants and their construction methods were authorized by the US Patent Office. Recently, it has been approved through the American Green Express Channel. This is the first domestic nasal injection vaccine that has obtained the US patent, and it is another major progress in Haihua Biological to develop new crown products independently.

According to reports, mucous membrane immunity is one of the most effective way to prevent the new crown virus, which has the characteristics of faster performance and wider immune response. While the patent uses mucosal immune technology, the innovative type uses nasal vaccination to form the first immune barrier to resist virus invasion in mucosa. The new crown vaccine prepared by this technical means has the characteristics of fast production, convenient use, and rapidly popularizing immunity by animal experiment tests. It can produce protective antibodies in 7 days.

Established in 2016, Haihua Biological is a national high -tech enterprise integrating biomedical research and development and testing technology services. The group business involves vaccine research and development, inspection and testing, and CRO services. At the beginning of the new crown epidemic in 2020, Haihua Biological was devoted to the development of the new Coronatte (SARS-COV-2) fast detection kit. Used by Wuhan University Central South Hospital. At the same time, the R & D work of MRNA vaccine with a nasal nasal vector carrier with completely independent intellectual property rights was carried out. The relevant patent was reviewed by the State Intellectual Property Office in August 2021 in August 2021.

It is understood that in addition to the research and development of the nasal spray-type new crown vaccine, Haihua Biological follows the infectious lesions and development. The kit (ELISA) and monkey acne virus nucleic acid diagnosis kit (fluorescent probe method), and obtained EU CE certification, with export qualifications. The first two products were also included in the Ministry of Commerce's medical insurance business association. (Qingdao Daily/Guanhai Journalist Li Xunxiang)

- END -